McKESSON REPORTS FISCAL 2007 FIRST QUARTER RESULTS

• Revenues of $23.6 billion, up 13%.

• Net income of $184 million, up 8%, and diluted EPS of 60 cents, up 9%.

• Fiscal 2007 outlook reaffirmed: diluted EPS from continuing operations of $2.55 to $2.70 per share, excluding adjustments to Securities Litigation reserves.

SAN FRANCISCO, July 27, 2006 — McKesson Corporation (NYSE: MCK) today reported that revenues for the first quarter ended June 30, 2006, were $23.6 billion, an increase of 13% from $21.0 billion in the first quarter a year ago. First quarter net income was $184 million, up 8% from $171 million a year ago, and diluted earnings per share was 60 cents, up 9% from 55 cents.

     First quarter results included a total of $26 million in previously announced pre-tax charges associated with McKesson’s investment in Parata Systems and a restructuring charge in Provider Technologies. The quarter also included $8 million in pre-tax share-based compensation expense as the FAS123R requirement took effect for the company. First quarter results a year ago included a $51 million pre-tax anti-trust settlement credit and a $52 million pre-tax charge to Securities Litigation expense.

     “McKesson is off to a solid start in Fiscal 2007, with strong momentum in our Pharmaceutical Solutions and Provider Technologies segments,” said John H. Hammergren, chairman and chief executive officer. “We are pleased with the balance we are achieving, continuing to deliver improved operating results in our core businesses while also deploying capital in a disciplined way to create additional shareholder value.”

     “Our activities in the quarter were an excellent example of how we take a balanced approach to our corporate strategy and use of capital. We made several acquisitions, sold non-strategic assets and continued to return capital to our shareholders through a steady repurchase of our shares and our quarterly dividend.”

     During the first quarter of Fiscal 2007, McKesson repurchased $283 million of common stock and on June 30, 2006, had $217 million remaining on the previous $500 million share repurchase authorization. At its most recent meeting, the company’s Board of Directors authorized an additional $500 million share repurchase and a six cent per share quarterly dividend. Cash flow from operations during the quarter was $295 million, and McKesson ended the quarter with a cash balance of $2 billion and a gross debt-to-capital ratio of 14%.

     “Our strong balance sheet and solid cash flow enable us to continue our portfolio approach to capital deployment,” said Hammergren. “Combined with consistently strong operating results from having focused businesses in attractive, growing markets for healthcare services, we believe we are well-positioned to deliver sustained shareholder value creation.”

Segment Results

     Pharmaceutical Solutions revenues were up 12% for the first quarter compared to the first quarter a year ago, resulting primarily from the acquisition of D&K Healthcare Resources (D&K) in August 2005, the impact of new and expanded warehouse sales agreements converting volume previously purchased directly from manufacturers by our large customers and revenue growth in Canada. Warehouse sales were up 17% in the quarter. Canadian revenues increased 18%, including a positive currency impact of 12%. Sales growth of 29% for McKesson’s proprietary OneStop generics program for retail pharmacies once again exceeded market growth.

2

     Pharmaceutical Solutions gross profit was up 8% in the first quarter to $644 million from $594 million in the first quarter a year ago, resulting from strong revenue growth, new agreements with pharmaceutical manufacturers, an increased mix of higher-margin generic products, stabilization of sell margin to customers and a $10 million LIFO credit. The gross profit comparison was especially strong considering that the first quarter this year includes $15 million of asset impairment charges associated with the Parata Systems investment while the first quarter a year ago benefited from receipt of a $51 million anti-trust settlement.

     During the first quarter, McKesson completed the integration of D&K operations and closed two duplicate D&K facilities. Incremental expenses associated with the D&K integration and the Parata Systems investment contributed to the increase in operating expenses in the quarter. Operating profit was $292 million compared to $302 million a year ago reflecting the impact of these expenses and last year’s favorable anti-trust settlement.

     “While generic conversions deflate revenue growth, we earn significantly more on these drugs compared to the branded versions,” said Hammergren. “Our generics opportunity should accelerate throughout the remainder of the fiscal year and this business should contribute even more strongly to our profits in succeeding quarters. We also expect operating expenses will return to a more normal growth rate by the second half of the year. Overall, we should make progress toward our goal of an annual operating margin rate of 150 to 200 basis points for this segment.”

     Medical-Surgical Solutions revenues were up 18% in the first quarter compared to the first quarter a year ago, reflecting in part an extra week of sales. Operating profit in the quarter was down 24% to $22 million.

3

     “Last quarter, we announced our intent to focus on the higher-growth, higher-margin alternate site sector of the medical-surgical market,” said Hammergren. “We were pleased to have quickly found an appropriate buyer for our non-strategic acute care business, one that we expect will continue to deliver the high levels of service and quality that have distinguished our operations.”

     “We have already begun to sharpen our focus on our opportunity to expand our industry-leading position in the alternate site sector of the market. Our acquisition of Sterling Medical further strengthens our presence in consumer healthcare by expanding our distribution of medical supplies direct to homecare patients. Once we have completed the sale and transition of the acute care business, we expect that our alternate site medical-surgical business, which currently has annual revenues of approximately $2 billion, will have an operating margin rate of 4 to 6%.”

     The pending sale of the acute care business is subject to regulatory review and other customary closing conditions. McKesson expects to report the results of its acute care business as a discontinued operation beginning in the second fiscal quarter.

     In Provider Technologies, revenues were up 19% for the first quarter compared to the first quarter a year ago. Software and software systems revenues increased 27%, driven by continued strong demand for clinical software, imaging solutions and automation systems, and increased implementations. Operating profit in the quarter was up 13% to $35 million, including a $5 million charge for a restructuring plan, from $31 million in the first quarter a year ago. Operating margin rate was 8.39% for the first quarter, including the impact of the restructuring charge.

4

     “We continue to see strong market demand and a very positive response by customers to the value of our solutions and quality of our implementations,” Hammergren said. “We’ve expanded our Paragon solutions for the small hospital market to include advanced nursing and medication safety capabilities, resulting in growing market momentum. In addition, Paragon is now the community hospital information system category leader in the latest KLAS vendor performance rankings, another factor in the traction we’re achieving.”

     “Over the past year, the market for ambulatory information solutions began to expand more rapidly, and the market for consumer-oriented healthcare information technology is now emerging. We combined our recent HealthCom and RelayHealth acquisitions with other solutions into a unit that will focus on interactive technologies designed to improve connectivity between providers, patients and payors and provide secure electronic access to personal health records, healthcare financial management systems and data from home diagnostics tools.”

     “We believe that the government’s July 18^th announcement certifying the ambulatory electronic health record products of certain vendors, including McKesson, will accelerate market adoption of ambulatory EHR solutions and systems that facilitate physician-to-physician and physician-to-patient connectivity. McKesson is uniquely positioned to offer a comprehensive solutions portfolio to physicians and patients. We plan to continue to increase our investments in ambulatory and consumer solutions to ensure that we maintain our market-leading position as demand accelerates.”

5

Outlook

     “I’m very pleased with our results for the first fiscal quarter and the momentum we take into the remaining three quarters of the year,” Hammergren said. “Our pharmaceutical distribution business continues to deliver steady growth. We are focused on operating margin expansion across all aspects of the business and we expect that sales of generic drugs will play an increasingly important role in our profitability as the year progresses. Demand remains strong for our healthcare information technology solutions within our historical customer base, and we believe we are now well-positioned with small hospitals and in the rapidly-expanding realm of physician offices and home healthcare.”

     “We continue to refine our corporate focus by increasing our investments in new opportunities and plan to continue to be disciplined about how we use our strong balance sheet to create additional shareholder value. Based on our first quarter results and the continued progress in our business, we are reaffirming our recently provided financial outlook. For the fiscal year ending March 31, 2007, McKesson expects to earn between $2.55 and $2.70 per fully diluted share from continuing operations, excluding adjustments to the Securities Litigation reserves.”

Corporate Highlights

     The first quarter of Fiscal 2007 included the following additional news at the company:

     • McKesson combined its retail pharmacy automation business with Parata Systems and made an investment in the combined company, and is now a significant minority investor in a stronger organization that has a market-leading product offering and more efficient operations.

6

     • McKesson continues to lead the pharmaceutical distribution industry in contract price accuracy, according to a comparative study of third-party pricing data validated by S/T Health Group Consulting, Inc., an independent healthcare consulting firm, which reviewed more than $1.89 billion of invoices from a variety of U.S. hospital pharmacies.

     • On July 1, McKesson and the Illinois Department of Healthcare and Family Services launched a comprehensive disease management program for more than 168,000 Illinois Medicaid beneficiaries who are disabled or chronically ill.

     • McKesson acquired HealthCom Partners LLC, a leading provider of virtual business office capabilities and consumer-interactive patient billing solutions, and RelayHealth Corporation, a leading provider of online physician-patient communication services.

     • On July 18, the Certification Commission on Healthcare Information Technology announced its first round of vendors that have passed certification requirements. McKesson’s Horizon Ambulatory Care, Release 9.4, passed 100% of the required criteria and is one of only 18 products on the market to carry the CCHIT-certified seal. In June, we signed a second agreement with Triad Hospitals, Inc., to install Horizon Ambulatory Care in 195 clinics across the country.

     • In the Top 20: KLAS 2006 Mid-Year Report Card issued in June by KLAS Enterprises, McKesson’s Paragon^® solution received the No. 1 ranking in the community hospital information system category and Horizon Medical Imaging™ was ranked No. 1 for the community PACS segment. In all, McKesson solutions are ranked in the top three for 16 KLAS categories, five of which are category leaders.

7

     • At its July meeting, the Board of Directors authorized a new repurchase from time to time of up to $500 million of the company’s shares of common stock in open market or private transactions. The Board’s authorization follows a previous $500 million share repurchase program authorized in April 2006, which has approximately $217 million remaining.

     • Due to the company’s strong balance sheet and cash flow, McKesson renewed its annual committed accounts receivable sales facility under substantially the same terms to those previously in place, with the exception that the facility amount was reduced from $1.4 billion to $700 million.

     • McKesson intends to withdraw its common stock from listing on NYSE Arca, Inc. (formerly the Pacific Stock Exchange) as a cost-saving measure and to reduce administrative costs. The company’s common stock will continue to be listed on the New York Stock Exchange.

Risk Factors

     Except for historical information contained in this press release, matters discussed may constitute “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These statements may be identified by their use of forward-looking terminology such as “believes”, “expects”, “anticipates”, “may”, “should”, “seeks”, “approximates”, “intends”, “plans”, “estimates” or the negative of these words or other comparable terminology. The most significant of these risks and uncertainties are described in the company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: adverse resolution of pending shareholder litigation regarding the 1999 restatement of our historical financial statements; the changing U.S. healthcare environment, including changes in government regulations and the

8

impact of potential future mandated benefits; competition; changes in private and governmental reimbursement or in the delivery systems for healthcare products and services; governmental and manufacturers’ efforts to regulate or control the pharmaceutical supply chain; changes in pharmaceutical and medical-surgical manufacturers’ pricing, selling, inventory, distribution or supply policies or practices; changes in the availability or pricing of generic drugs; changes in customer mix; substantial defaults in payment or a material reduction in purchases by large customers; challenges in integrating and implementing the company’s internally used or externally sold software and software systems, or the slowing or deferral of demand or extension of the sales cycle for external software products; continued access to third-party licenses for software and the patent positions of the company’s proprietary software; the company’s ability to meet performance requirements in its disease management programs; the adequacy of insurance to cover liability or loss claims; new or revised tax legislation; foreign currency fluctuations or disruptions to foreign operations; the company’s ability to successfully identify, consummate and integrate strategic acquisitions; changes in generally accepted accounting principles (GAAP) and general economic conditions. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The company assumes no obligation to update or revise any such statements, whether as a result of new information or otherwise.

     A Webcast of the company’s regular conference call to review financial results with the financial community is available through McKesson’s website, www.mckesson.com, live at 5 PM ET today and on replay afterwards. Shareholders are encouraged to review SEC filings and more information about McKesson, which are located on the company’s website.

About McKesson

     McKesson Corporation (NYSE: MCK) is a Fortune 16 healthcare services and information technology company dedicated to helping its customers deliver high-quality healthcare by reducing costs, streamlining processes and improving the quality and safety of patient care. Over the course of its 173-year history,

9

McKesson has grown by providing pharmaceutical and medical-surgical supply management across the spectrum of care; healthcare information technology for hospitals, physicians, homecare and payors; hospital and retail pharmacy automation; and services for manufacturers and payors designed to improve outcomes for patients. For more information, visit us at www.mckesson.com.

###

CONTACT:
Larry Kurtz, 415-983-8418
(Investors and Financial Press)
larry.kurtz@mckesson.com
Kate Rohrbach 415-983-9023
(Business and Trade Media)
kate.rohrbach@mckesson.com

10

Schedule I

McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in millions except per share amounts)

	Quarter Ended June 30,
	FY07			FY06			Chg.
Revenues	$	23,616		$	20,968			13	%
Cost of sales		22,593			20,043			13
Gross profit		1,023			925			11
Operating expenses		751			612			23
Securities Litigation charges, net		—			52			(100	)
Total operating expenses		751			664			13
Operating income		272			261			4
Interest expense		(22	)		(25	)		(12	)
Other income, net		35			28			25
Income from continuing operations before income taxes		285			264			8
Income taxes		(101	)		(94	)		7
Income from continuing operations		184			170			8
Discontinued operation, net		—			1			(100	)
Net income	$	184		$	171			8
Earnings per common share (1)
Diluted	$	0.60		$	0.55			9	%
Basic		0.61			0.57			7
Weighted average shares outstanding
Diluted		309			313			(1	)%
Basic		302			302			—	%

(1) For purposes of calculating diluted earnings per share, interest expense, net of related income taxes, of $1 million was added to net income for the quarter ended June 30, 2005. This adjustment reflects the impact of the Company’s potentially dilutive obligations.

Schedule II

McKESSON CORPORATION
CONDENSED CONSOLIDATED INCOME INFORMATION BY BUSINESS SEGMENT
(unaudited)
(in millions)

	Quarter Ended June 30,
	FY07			FY06			Chg.
REVENUES
Pharmaceutical Solutions
U.S. Healthcare direct distribution & services	$	13,480		$	12,309			10	%
U.S. Healthcare sales to customers’ warehouses		7,094			6,078			17
Subtotal		20,574			18,387			12
Canada distribution & services		1,750			1,487			18
Total Pharmaceutical Solutions		22,324			19,874			12
Medical-Surgical Solutions		875			744			18
Provider Technologies
Software & software systems		79			62			27
Services		297			254			17
Hardware		41			34			21
Total Provider Technologies		417			350			19
Revenues	$	23,616		$	20,968			13
GROSS PROFIT
Pharmaceutical Solutions	$	644		$	594			8
Medical-Surgical Solutions		190			169			12
Provider Technologies		189			162			17
Gross profit	$	1,023		$	925			11
OPERATING EXPENSES
Pharmaceutical Solutions	$	364		$	300			21
Medical-Surgical Solutions		169			141			20
Provider Technologies		156			133			17
Corporate		62			38			63
Subtotal		751			612			23
Securities Litigation charges, net		—			52			(100	)
Operating expenses	$	751		$	664			13
OTHER INCOME, NET
Pharmaceutical Solutions	$	12		$	8			50
Medical-Surgical Solutions		1			1			—
Provider Technologies		2			2			—
Corporate		20			17			18
Other income, net	$	35		$	28			25
OPERATING PROFIT
Pharmaceutical Solutions	$	292		$	302			(3	)
Medical-Surgical Solutions		22			29			(24	)
Provider Technologies		35			31			13
Operating profit		349			362			(4	)
Corporate		(42	)		(21	)		100
Securities Litigation charges		—			(52	)		(100	)
Income from continuing operations before interest expense and income taxes	$	307		$	289			6
STATISTICS
Operating profit as a % of revenues
Pharmaceutical Solutions		1.31	%		1.52	%		(21	) bp
Medical-Surgical Solutions		2.51	%		3.90	%		(139	)
Provider Technologies		8.39	%		8.86	%		(47	)
Return on Stockholders’ Equity (1)		13.0	%		(2.8	%)

(1) Ratio is computed as the sum of net income (loss) for the last four quarters, divided by the average of stockholders’ equity for the last five quarters. Ratios include the Securities Litigation charges.

Schedule III

McKESSON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions)

	June 30,		March 31,
	2006		2006
ASSETS
Current Assets
Cash and cash equivalents	$	2,000	$	2,142
Restricted cash		981		962
Receivables, net		6,249		6,370
Inventories		7,714		7,260
Prepaid expenses and other		168		162
Total		17,112		16,896
Property, Plant and Equipment, net		644		671
Capitalized Software Held for Sale		143		139
Goodwill		1,786		1,718
Intangible Assets		133		128
Other Assets		1,521		1,400
Total Assets	$	21,339	$	20,952
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Drafts and accounts payable	$	10,389	$	10,055
Deferred revenue		828		827
Current portion of long-term debt		26		26
Securities Litigation		1,008		1,014
Other		1,574		1,570
Total		13,825		13,492
Postretirement Obligations and Other Noncurrent Liabilities		643		588
Long-Term Debt		962		965
Stockholders’ Equity		5,909		5,907
Total Liabilities and Stockholders’ Equity	$	21,339	$	20,952

Schedule IV

McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in millions)

	Three Months Ended June 30,
	FY07			FY06
OPERATING ACTIVITIES
Net income	$	184		$	171
Adjustments to reconcile to net cash provided by (used in) operating activities:
Depreciation and amortization		70			64
Securities Litigation charges, net		—			52
Deferred taxes		58			33
Other non-cash items		12			(1	)
Total		324			319
Effects of changes in:
Receivables		135			(23	)
Inventories		(446	)		262
Drafts and accounts payable		305			48
Deferred revenue		25			129
Taxes		40			18
Securities Litigation settlement payments		(6	)		(31	)
Other		(82	)		(84	)
Total		(29	)		319
Net cash provided by operating activities		295			638
INVESTING ACTIVITIES
Property acquisitions		(26	)		(44	)
Capitalized software expenditures		(48	)		(32	)
Acquisitions of businesses, less cash and cash equivalents acquired		(91	)		(8	)
Other		(39	)		(8	)
Net cash used in investing activities		(204	)		(92	)
FINANCING ACTIVITIES
Repayment of debt		(3	)		(11	)
Capital stock transactions:
Issuances		60			155
Share repurchases		(283	)		(66	)
ESOP notes and guarantees		2			3
Dividends paid		(18	)		(18	)
Other		9			—
Net cash provided by (used in) financing activities		(233	)		63
Net increase (decrease) in cash and cash equivalents		(142	)		609
Cash and cash equivalents at beginning of period		2,142			1,800
Cash and cash equivalents at end of period	$	2,000		$	2,409